DVT prophylaxis in total joint reconstruction.
Deep venous thrombosis (DVT) is the end result of a complex interaction of events including the activation of the clotting cascade in conjunction with platelet aggregation. Patients undergoing major lower extremity orthopedic surgery, especially total joint arthroplasty (TJA), are at high risk for developing a postoperative DVT or a subsequent pulmonary embolus. Venous thromboembolic (VTE) prophylaxis, most commonly pharmacologic prophylaxis, has become the standard of care for patients undergoing elective TJA. However, the controversy between the efficacy of VTE prophylaxis and the increased risk for bleeding in the postoperative period continues to exist. This review addresses the controversy underlying VTE prophylaxis by outlining 2 guidelines and demonstrating the pros and cons of different DVT prophylaxis regimens based on the available evidence-based literature.
Sheth
Neil P
NP
Department of Orthopaedic Surgery, Rush University, Midwest Orthopaedics, 1725 West Harrison Street, Chicago, IL 60612, USA.
Lieberman
Jay R
JR
Della Valle
Craig J
CJ
D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use; D019643:Arthroplasty, Replacement / Q000009:adverse effects*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage; D004347:Drug Interactions; D006801:Humans; D019934:International Normalized Ratio; D011183:Postoperative Complications / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D020246:Venous Thrombosis / Q000517:prevention & control*; D014859:Warfarin / Q000494:pharmacology / Q000627:therapeutic use
D000925:Anticoagulants; D014859:Warfarin; D001241:Aspirin